Skip to main content
OTLC
OTC Life Sciences

Oncotelic 10-Q: Going Concern, Debt Defaults, and Dilutive Financing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.047
Mkt Cap
$20.989M
52W Low
$0.015
52W High
$0.11
52W Position info
215% above low
Off High info
57% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

OTLC has more than doubled off its 52-week low of $0.015 on elevated volume (1.8× avg).

Summary

Oncotelic's Q2 2026 10-Q shows a going concern warning, $5M debt default, and new dilutive convertible notes, offset by a one-time gain from the Lunai merger.


Key Events · Earnings and Guidance · OTLC

  • Going Concern Warning

    Management states substantial doubt about the company's ability to continue as a going concern, with only $206K cash and $16.4M negative working capital as of June 30, 2026.

  • Debt Default

    The company is in default on approximately $5.0M of Forever Prosperity Notes (formerly GMP Notes) for failure to pay principal and interest at maturity.

  • Dilutive Convertible Notes

    New notes with Pacific Pier ($178,410) and Mast Hill ($398,333) carry conversion prices at discounts to market, with Pacific Pier's at the lesser of $0.06 or 85% of the lowest recent trading price.

  • Lunai Merger Gain

    The completed Lunai Bioworks merger resulted in a $1.1M gain on derecognition of a non-financial asset and a $0.3M fair value gain on the received Series B preferred stock.


Analysis · OTLC · Life Sciences

Oncotelic's Q2 2026 report reveals a company in severe financial distress. Cash is only $206K against $16.4M negative working capital, and management states substantial doubt about its ability to continue as a going concern. The company is in default on $5.0M of Forever Prosperity notes and has been forced into highly dilutive convertible notes with Pacific Pier and Mast Hill that convert at discounts to market. While the Lunai merger provided a one-time $1.4M non-cash gain, it does not solve the cash crisis. The Nasdaq uplisting application is a positive step but remains uncertain.

At the time of this filing, OTLC was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $21M. The 52-week trading range was $0.02 to $0.11. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OTLC - Latest Insights

OTLC
Aug 04, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
OTLC
Jun 29, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
OTLC
Jun 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
OTLC
Jun 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
OTLC
May 14, 2026, 5:21 PM EDT
Source: Wiseek News
Importance Score:
7